ANUHPHR91.70

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹919 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)58.68105.65105.65
Receivable Days (DSO)119.11112.88112.88
Payable Days (DPO)123.57134.19102.17
Cash Conversion Cycle (days)54.2284.34116.36
Working Capital Turnover3.353.113.89
Asset Turnover1.311.381.38
Cash Conversion (CFO/Net Income)0.78-0.07-0.07
CFO/EBITDA0.61-0.05-0.05
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.